Therapeutic Area | MeSH |
---|---|
neoplasms | D009369 |
urogenital diseases | D000091642 |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
CASODEX | ANI Pharmaceuticals | N-020498 RX | 1995-10-04 | 1 products, RLD, RS |
Brand Name | Status | Last Update |
---|---|---|
bicalutamide | New Drug Application | 2024-11-14 |
casodex | New Drug Application | 2023-12-18 |
esterified estrogens and methyltestosterone | unapproved drug other | 2011-03-09 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
prostatic neoplasms | — | D011471 | C61 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Prostatic neoplasms | D011471 | — | C61 | 2 | — | — | — | — | 2 |
Hirsutism | D006628 | HP_0001007 | L68.0 | 2 | — | — | — | — | 2 |
Drug common name | Bicalutamide |
INN | bicalutamide |
Description | N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide is a member of the class of (trifluoromethyl)benzenes that is 4-amino-2-(trifluoromethyl)benzonitrile in which one of the amino hydrogens is substituted by a 3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanoyl group. It is a member of (trifluoromethyl)benzenes, a monocarboxylic acid amide, a member of monofluorobenzenes, a nitrile, a sulfone and a tertiary alcohol. |
Classification | Small molecule |
Drug class | non-steroid antiandrogens |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1 |
PDB | — |
CAS-ID | 90357-06-5 |
RxCUI | — |
ChEMBL ID | CHEMBL409 |
ChEBI ID | — |
PubChem CID | 2375 |
DrugBank | DB01128 |
UNII ID | A0Z3NAU9DP (ChemIDplus, GSRS) |